drug
esketamine hydrochloride
Marketedupdated 6mo agoby Johnson & Johnson Innovative Medicine
Approvedannual revenue · 2024–2024peak $1.0B
community read0 votes
🐶 often sniffed alongside
top 5indications
investigational
Major Depression
all catalysts(1)
Trials studying esketamine hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 20, 2027
120 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Feb 18, 2040method-of-use (U-3813)US 11883526
- Sep 10, 2035method-of-use (U-3036)US 10869844
- Sep 10, 2035method-of-use (U-3257)US 11173134
- Sep 10, 2035method-of-use (U-3035)US 11311500
- Mar 14, 2034method-of-use (U-3446)US 11446260
- Mar 5, 2033method-of-use (U-4112)US 8785500
- Mar 20, 2027method-of-use (U-4112)US 9592207120d
FDA exclusivities (1)
- Jan 17, 2028I-959Indication (3y)1.2y
News(10)
- HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s DayIbogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.biospace · 6d ago
- ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veteransThe U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).fiercebiotech · 7d ago
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 9d ago
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 9d ago
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.fiercebiotech · 10d ago
- Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”stat · 1mo ago
- How J&J paved the way for Compass’ coming psychedelic drug launchIn an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…biopharma_dive · 1mo ago
- Deep dive: Psychedelics back on FDA’s doorstepBioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.biospace · 2mo ago
- Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near marketSafety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…biospace · 2mo ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that